Lilly Asia et al Fund Central Nervous System Drug Development
29 Jan 2026
US$ 20.00
Lilly Asia Ventures has led the series A+ financing round of NeuShen Therapeutics Inc (NeuShen), joined by Pivotal...
Related Publications
Subscribers’ Weekly for the week ending 30 Jan 2026...
Listen to Australia/New Zealand Investments (Subscribers' Weekly 30 Jan 2026)...
Connect With Us
We love to share Asia PE insights and news from time to time. Drop us your email address if you like to hear from us.
Rest assured that your email address will not be shared, as we hate spams as much as you do.